8-K Announcements
6Material company update
Mar 31, 2026·SEC
Material company update
Jan 7, 2026·SEC
Material company update
Dec 29, 2025·SEC
Omeros Corporation(OMER)Earnings, Financials & Key Ratios
OMER•NASDAQ
$14.77
$1.03B mkt cap·Price updated May 6, 2026
AboutOmeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.Show more
- Revenue$0
- EBITDA-$168M-2.9%
- Net Income-$157M-33.1%
- EPS (Diluted)-2.70-43.6%
- ROIC-72.43%-119.0%
- Interest Coverage-6.86+39.5%
OMER Key Insights
Omeros Corporation (OMER) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 94 (top 6%)
- ✓Share count reduced 7.3% through buybacks
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
OMER Price & Volume
Omeros Corporation (OMER) stock price & volume — 10-year historical chart
Loading chart...
OMER Growth Metrics
Omeros Corporation (OMER) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM9.94%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM12.55%
Return on Capital
10 Years-134.75%
5 Years-70.72%
3 Years-48.92%
Last Year-64.79%
OMER Recent Earnings
Omeros Corporation (OMER) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
Mar 31, 2026EPS
$3.14
Est $0.55
+670.9%
Revenue
—
Est $2M
Q4 2025
Nov 13, 2025EPS
$0.19
Est $0.58
+67.2%
Revenue
—
Q3 2025
Aug 14, 2025EPS
$0.53
Est $0.55
+3.6%
Revenue
—
Est $312,500
Q2 2025
May 15, 2025EPS
$0.65
Est $0.57
-14.0%
Revenue
—
Est $416,670
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 31, 2026 | $3.14vs $0.55+670.9% | —vs $2M |
| Q4 2025 | Nov 13, 2025 | $0.19vs $0.58+67.2% | — |
| Q3 2025 | Aug 14, 2025 | $0.53vs $0.55+3.6% | —vs $312,500 |
| Q2 2025 | May 15, 2025 | $0.65vs $0.57-14.0% | —vs $416,670 |
Based on last 12 quarters of dataView full earnings history →
OMER Peer Comparison
Omeros Corporation (OMER) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.78B | 22.35 | 16.43 | 31.85% | 24.94% | 28.47% | 4.16% | 0.07 |
 PTCT | 5.39B | 65.04 | 8.36 | 114.51% | 39.44% | 13.02% | ||
 RARE | 2.46B | 25.01 | -4.29 | 20.13% | -85.54% | -9.11% | ||
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 HALO | 7.76B | 65.87 | 25.73 | 37.55% | 22.69% | 6.49% | 8.31% | |
 PRTA | 602.39M | 11.19 | -2.47 | -92.84% | -25.21% | -73% | 0.05 | |
 BCAB | 5.38M | 4.57 | -0.09 | -81.82% | -29.8% | |||
 APLS | 5.19B | 40.97 | 227.61 | -11.77% | 3.25% | 7.48% | 0.87% | 0.30 |
Compare OMER vs Peers
Omeros Corporation (OMER) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OMER Income Statement
Omeros Corporation (OMER) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 41.62M | 64.83M | 29.87M | 111.81M | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | 208.07% | 55.77% | -53.93% | 274.33% | -100% | - | - | - | - | - |
| Cost of Goods Sold | 1.41M | 1.08M | 512K | 2.65M | 1.62M | 1.39M | 0 | 0 | 0 | 10.59M |
| COGS % of Revenue | 3.39% | 1.66% | 1.71% | 2.37% | - | - | - | - | - | - |
| Gross Profit | 40.2M▲ 0% | 63.75M▲ 58.6% | 29.36M▼ 53.9% | 109.15M▲ 271.8% | -1.62M▼ 101.5% | -1.39M▲ 14.2% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | -10.59M▲ 0% |
| Gross Margin % | 96.61% | 98.34% | 98.29% | 97.63% | - | - | - | - | - | - |
| Gross Profit Growth % | 222.47% | 58.56% | -53.95% | 271.81% | -101.48% | 14.23% | 100% | - | - | - |
| Operating Expenses | 94.48M | 107.64M | 141.58M | 172.53M | 155.3M | 172.23M | 163.39M | 164.53M | 169.26M | 118.78M |
| OpEx % of Revenue | 227.02% | 166.05% | 474.01% | 154.32% | - | - | - | - | - | - |
| Selling, General & Admin | 43.78M | 52.04M | 51.72M | 62.84M | 47.69M | 53.46M | 50.67M | 49.66M | 49.73M | 33.86M |
| SG&A % of Revenue | 105.2% | 80.28% | 173.16% | 56.2% | - | - | - | - | - | - |
| Research & Development | 50.7M | 55.6M | 89.86M | 109.7M | 107.61M | 118.78M | 112.72M | 114.87M | 119.52M | 84.87M |
| R&D % of Revenue | 121.82% | 85.77% | 300.86% | 98.11% | - | - | - | - | - | - |
| Other Operating Expenses | 945K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 52K |
| Operating Income | -54.28M▲ 0% | -43.9M▲ 19.1% | -112.22M▼ 155.7% | -63.38M▲ 43.5% | -156.92M▼ 147.6% | -173.62M▼ 10.6% | -163.39M▲ 5.9% | -164.53M▼ 0.7% | -169.26M▼ 2.9% | -129.38M▲ 0% |
| Operating Margin % | -130.42% | -67.71% | -375.73% | -56.69% | - | - | - | - | - | - |
| Operating Income Growth % | 23.81% | 19.13% | -155.66% | 43.52% | -147.57% | -10.64% | 5.89% | -0.7% | -2.87% | - |
| EBITDA | -53.98M | -43.34M | -111.26M | -61.59M | -155.3M | -172.23M | -162.44M | -163.61M | -168.31M | -126.61M |
| EBITDA Margin % | -129.7% | -66.86% | -372.51% | -55.09% | - | - | - | - | - | - |
| EBITDA Growth % | 24.01% | 19.7% | -156.69% | 44.64% | -152.15% | -10.9% | 5.69% | -0.72% | -2.87% | 26.61% |
| D&A (Non-Cash Add-back) | 300K | 551K | 962K | 1.79M | 1.62M | 1.39M | 952K | 920K | 950K | 2.77M |
| EBIT | -58.93M | -42.45M | -123.43M | -61.83M | -169.64M | -171.88M | -159.33M | -144.08M | -157.95M | -117.19M |
| Net Interest Income | -7.82M | -11.03M | -16.25M | -22.66M | -26.1M | -19.65M | -18.64M | -14.5M | -13.37M | -16.66M |
| Interest Income | 0 | 0 | 0 | 0 | 654K | 17.93K | 4.06M | 0 | 11.3M | 3.54M |
| Interest Expense | 7.82M | 11.03M | 16.25M | 22.66M | 26.75M | 19.67M | 22.7M | 14.5M | 24.68M | 20.2M |
| Other Income/Expense | -12.47M | -9.59M | -27.46M | -21.1M | -39.47M | -17.93M | -18.64M | -10.39M | -13.37M | -1.54M |
| Pretax Income | -66.75M▲ 0% | -53.48M▲ 19.9% | -139.69M▼ 161.2% | -84.49M▲ 39.5% | -196.39M▼ 132.5% | -191.55M▲ 2.5% | -182.03M▲ 5.0% | -174.92M▲ 3.9% | -182.63M▼ 4.4% | -130.91M▲ 0% |
| Pretax Margin % | -160.38% | -82.5% | -467.68% | -75.57% | - | - | - | - | - | - |
| Income Tax | 0 | 0 | -12.93M | 0 | -23.26M | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 9.26% | 0% | 11.84% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -66.75M▲ 0% | -53.48M▲ 19.9% | -126.76M▼ 137.0% | -84.49M▲ 33.3% | -138.06M▼ 63.4% | -111.41M▲ 19.3% | 47.42M▲ 142.6% | -117.81M▼ 348.5% | -156.81M▼ 33.1% | -121.16M▲ 0% |
| Net Margin % | -160.38% | -82.5% | -424.39% | -75.57% | - | - | - | - | - | - |
| Net Income Growth % | 11.12% | 19.87% | -137.01% | 33.35% | -63.41% | 19.3% | 142.56% | -348.46% | -33.11% | 9.94% |
| Net Income (Continuing) | -66.75M | -53.48M | -126.76M | -84.49M | -173.13M | -191.55M | -182.03M | -174.92M | -182.63M | -130.91M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 35.07M | 80.13M | 229.45M | 57.11M | 25.81M | 2.46M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.65▲ 0% | -1.17▲ 29.1% | -2.61▼ 123.1% | -2.16▲ 17.2% | -2.41▼ 11.6% | 3.12▲ 229.5% | 0.46▼ 85.3% | -1.88▼ 508.7% | -2.70▼ 43.6% | -1.83▲ 0% |
| EPS Growth % | 17.5% | 29.09% | -123.08% | 17.24% | -11.57% | 229.46% | -85.26% | -508.7% | -43.62% | 12.55% |
| EPS (Basic) | -1.65 | -1.17 | -2.61 | -2.16 | -2.41 | 3.12 | 0.46 | -1.88 | -2.70 | - |
| Diluted Shares Outstanding | 40.45M | 45.54M | 48.58M | 49.52M | 57.18M | 62.34M | 62.74M | 62.74M | 58.17M | 66.26M |
| Basic Shares Outstanding | 40.45M | 45.54M | 48.58M | 49.52M | 57.18M | 62.34M | 62.74M | 62.74M | 58.17M | 66.26M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
OMER Balance Sheet
Omeros Corporation (OMER) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 60.26M | 108.37M | 89.87M | 103.75M | 151.28M | 247.96M | 443.24M | 217.9M | 134.12M | 71.81M |
| Cash & Short-Term Investments | 45.33M | 83.75M | 60.5M | 60.79M | 134.95M | 157.27M | 194.92M | 171.85M | 90.13M | 36.09M |
| Cash Only | 2.22M | 3.39M | 5.86M | 3.08M | 10.5M | 100.81M | 11.01M | 7.11M | 3.4M | 2.4M |
| Short-Term Investments | 43.11M | 80.36M | 54.64M | 57.7M | 124.45M | 56.46M | 183.91M | 164.74M | 86.73M | 33.69M |
| Accounts Receivable | 12.04M | 17.14M | 22.82M | 35.19M | 3.84M | 82.47M | 242.02M | 6.72M | 36.82M | 31.96M |
| Days Sales Outstanding | 105.57 | 96.53 | 278.85 | 114.87 | - | - | - | - | - | - |
| Inventory | 1.13M | 443K | 52.51M | 1.15M | 1.35M | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 291.59 | 150 | 37.43K | 157.69 | 306.05 | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 6.46M | 6.63M | 681K | 67K | 6.3M | 30.75M | 7.17M | 3.76M |
| Total Non-Current Assets | 7.02M | 7.96M | 6.07M | 33.22M | 29.76M | 171.31M | 147.73M | 160.37M | 142.96M | 113.9M |
| Property, Plant & Equipment | 1.18M | 2.12M | 3.85M | 30.91M | 28.08M | 30.01M | 23.25M | 20.58M | 17.64M | 13.82M |
| Fixed Asset Turnover | 35.24x | 30.56x | 7.77x | 3.62x | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 5.83M | 5.83M | 1.15M | 1.15M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 1.07M | 1.16M | 1.68M | 141.31M | 124.48M | 139.79M | 125.32M | 463.81M |
| Total Assets | 67.28M▲ 0% | 116.33M▲ 72.9% | 95.94M▼ 17.5% | 136.97M▲ 42.8% | 181.04M▲ 32.2% | 419.27M▲ 131.6% | 590.97M▲ 41.0% | 378.27M▼ 36.0% | 277.08M▼ 26.8% | 185.71M▲ 0% |
| Asset Turnover | 0.62x | 0.56x | 0.31x | 0.82x | - | - | - | - | - | 0.00x |
| Asset Growth % | 37.32% | 72.91% | -17.53% | 42.77% | 32.18% | 131.59% | 40.95% | -35.99% | -26.75% | -157.44% |
| Total Current Liabilities | 16.07M | 26.31M | 37.36M | 55.46M | 36.74M | 51.79M | 136.38M | 53.32M | 79.53M | 80.76M |
| Accounts Payable | 2.52M | 6.69M | 6.28M | 5.33M | 4.2M | 13.4M | 5.99M | 7.71M | 5.91M | 12.5M |
| Days Payables Outstanding | 651.16 | 2.27K | 4.48K | 732.47 | 948.41 | 3.53K | - | - | - | 272.66 |
| Short-Term Debt | 198K | 490K | 889K | 3.5M | 0 | 0 | 94.38M | 8.58M | 21M | 17.04M |
| Deferred Revenue (Current) | -198K | -490K | -889K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 8.61M | 16.46M | 26.58M | 43.08M | 3.95M | 3.71M | 7.82M | 0 | 29.51M | 31.44M |
| Current Ratio | 3.75x | 4.12x | 2.41x | 1.87x | 4.12x | 4.79x | 3.25x | 4.09x | 1.69x | 1.69x |
| Quick Ratio | 3.68x | 4.10x | 1.00x | 1.85x | 4.08x | 4.79x | 3.25x | 4.09x | 1.69x | 1.69x |
| Cash Conversion Cycle | -254 | -2.02K | 33.24K | -459.92 | - | - | - | - | - | - |
| Total Non-Current Liabilities | 88.65M | 92.83M | -41.58M | 190.53M | 265.06M | 343.7M | 368.9M | 349.94M | 380.16M | 325.43M |
| Long-Term Debt | 79.51M | 83.31M | 148.98M | 158.21M | 236.29M | 313.46M | 220.91M | 329.7M | 166.58M | 159.56M |
| Capital Lease Obligations | 324K | 810K | 1.58M | 32.32M | 28.77M | 29.13M | 22.43M | 18.14M | 13.47M | 44.63M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 8.82M | 8.72M | 8.18M | 0 | 0 | 1.11M | 125.57M | 2.09M | 200.11M | 544.23M |
| Total Liabilities | 104.72M | 119.14M | -4.22M | 245.99M | 301.79M | 395.49M | 505.29M | 403.25M | 459.69M | 406.18M |
| Total Debt | 79.71M | 84.61M | 151.45M | 194.03M | 268.84M | 347.84M | 342.02M | 361.58M | 207.02M | 191.61M |
| Net Debt | 77.49M | 81.21M | 145.59M | 190.95M | 258.34M | 247.03M | 331.01M | 354.48M | 203.62M | 189.21M |
| Debt / Equity | - | - | 0.23x | - | - | 14.63x | 3.99x | - | - | -0.87x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.51x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.49x |
| Interest Coverage | -6.94x | -3.98x | -6.91x | -2.80x | -5.87x | -8.83x | -7.20x | -11.35x | -6.86x | -5.80x |
| Total Equity | -37.45M▲ 0% | -2.81M▲ 92.5% | 650.13M▲ 23203.2% | -109.02M▼ 116.8% | -120.75M▼ 10.8% | 23.78M▲ 119.7% | 85.68M▲ 260.3% | -24.98M▼ 129.2% | -182.61M▼ 630.9% | -220.48M▲ 0% |
| Equity Growth % | -42.74% | 92.49% | 23203.23% | -116.77% | -10.76% | 119.69% | 260.32% | -129.16% | -630.93% | -956.87% |
| Book Value per Share | -0.93 | -0.06 | 13.38 | -2.20 | -2.11 | 0.38 | 1.37 | -0.40 | -3.14 | -3.33 |
| Total Shareholders' Equity | -37.45M | -2.81M | 650.13M | -109.02M | -120.75M | 23.78M | 85.68M | -24.98M | -182.61M | -220.48M |
| Common Stock | 438K | 482K | 490K | 542K | 616K | 626K | 628K | 611K | 580K | 700K |
| Retained Earnings | -469.89M | -523.37M | 650.13M | -734.61M | -872.67M | -683.13M | -635.72M | -753.53M | -910.35M | -1B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2.73M | -3.28M | -4.25M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OMER Cash Flow Statement
Omeros Corporation (OMER) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -51.5M | -36.23M | -103.74M | -60.07M | -100.09M | -109.72M | -86.48M | 74.73M | -148.8M | -148.8M |
| Operating CF Margin % | -123.76% | -55.88% | -347.32% | -53.73% | - | - | - | - | - | - |
| Operating CF Growth % | 21.02% | 29.66% | -186.35% | 42.09% | -66.61% | -9.63% | 21.18% | 186.41% | -299.13% | 125.67% |
| Net Income | -66.75M | -53.48M | -126.76M | -84.49M | -138.06M | -191.55M | -182.03M | -117.81M | -156.81M | -121.16M |
| Depreciation & Amortization | 300K | 551K | 962K | 1.79M | 1.62M | 1.39M | 952K | 920K | 950K | 1.03M |
| Stock-Based Compensation | 13.58M | 12.69M | 11.71M | 13.79M | 14.93M | 0 | 0 | 11.65M | 10.49M | 6.43M |
| Deferred Taxes | 5.59M | 0 | -12.93M | 0 | -12.01M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.98M | 4.19M | 18.98M | 9.23M | 25.86M | 94.54M | 213.56M | -67.45M | -33.17M | -29.68M |
| Working Capital Changes | -6.21M | -172K | 4.29M | -394K | 7.58M | -14.11M | -118.97M | 247.42M | 29.74M | 42.25M |
| Change in Receivables | -5.52M | -5.11M | -6.17M | -12.37M | 31.34M | -34.31M | -175.07M | 245.72M | 40.01M | 41.02M |
| Change in Inventory | -656K | 685K | 355K | -1.06M | -208K | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -319K | 9.52M | 10.54M | 13.28M | -19.74M | 14.64M | -10.66M | 0 | 0 | -4.98M |
| Cash from Investing | -16.34M | -37.6M | 25.15M | -3.4M | -67.03M | 193.71M | -127.56M | 27.45M | 82.22M | 87.93M |
| Capital Expenditures | -126K | -350K | -567K | -334K | -283K | -277K | -113K | -426K | -165K | -91K |
| CapEx % of Revenue | 0.3% | 0.54% | 1.9% | 0.3% | - | - | - | - | - | - |
| Acquisitions | 126K | 0 | 0 | 3.07K | 0 | 125.99M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -126K | -37.25K | 25.72K | -3.07K | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 68.7M | 75M | 81.05M | 60.7M | 174.53M | 6.32M | 124.25M | -106.08M | 62.88M | 18.18M |
| Debt Issued (Net) | 24.16M | -431K | 109.62M | -1.14M | 98.2M | -1.82M | 123.83M | -101.58M | -41.34M | -20.28M |
| Equity Issued (Net) | 38.04M | 63.66M | 0 | 54.24M | 93.67M | 8.38M | 415K | -4.65M | -11.85M | 35.68M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.65M | -11.85M | 0 |
| Other Financing | 6.5M | 11.77M | -28.57M | 7.6M | -17.34M | -241K | 0 | 150K | 116.07M | 2.78M |
| Net Change in Cash | 859K▲ 0% | 1.17M▲ 36.2% | 2.47M▲ 110.9% | -2.78M▼ 212.6% | 7.42M▲ 367.1% | 90.31M▲ 1117.6% | -89.8M▼ 199.4% | -3.9M▲ 95.7% | -3.71M▲ 5.1% | 874K▲ 0% |
| Free Cash Flow | -51.63M▲ 0% | -36.58M▲ 29.2% | -104.3M▼ 185.2% | -60.41M▲ 42.1% | -100.37M▼ 66.2% | -110M▼ 9.6% | -86.6M▲ 21.3% | 74.3M▲ 185.8% | -148.97M▼ 300.5% | -105.32M▲ 0% |
| FCF Margin % | -124.06% | -56.42% | -349.22% | -54.03% | - | - | - | - | - | - |
| FCF Growth % | 21.11% | 29.16% | -185.16% | 42.09% | -66.15% | -9.59% | 21.28% | 185.8% | -300.5% | 32.01% |
| FCF per Share | -1.28 | -0.80 | -2.15 | -1.22 | -1.76 | -1.76 | -1.38 | 1.18 | -2.56 | -2.56 |
| FCF Conversion (FCF/Net Income) | 0.77x | 0.68x | 0.82x | 0.71x | 0.72x | 0.98x | -1.82x | -0.63x | 0.95x | 0.87x |
| Interest Paid | 0 | 0 | 0 | 0 | 11.6M | 0 | 0 | 29.92M | 35.69M | 24.09M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.29M | 165K | 56K |
OMER Key Ratios
Omeros Corporation (OMER) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -39.16% | -31.23% | - | -468.52% | 86.63% | -388.17% | - | 57.33% |
| Return on Invested Capital (ROIC) | -130.72% | -55.59% | -19.26% | -10.83% | -107.22% | -63.77% | -35.65% | -33.07% | -72.43% | -72.43% |
| Gross Margin | 96.61% | 98.34% | 98.29% | 97.63% | - | - | - | - | - | - |
| Net Margin | -160.38% | -82.5% | -424.39% | -75.57% | - | - | - | - | - | - |
| Debt / Equity | - | - | 0.23x | - | - | 14.63x | 3.99x | - | - | -0.87x |
| Interest Coverage | -6.94x | -3.98x | -6.91x | -2.80x | -5.87x | -8.83x | -7.20x | -11.35x | -6.86x | -5.80x |
| FCF Conversion | 0.77x | 0.68x | 0.82x | 0.71x | 0.72x | 0.98x | -1.82x | -0.63x | 0.95x | 0.87x |
| Revenue Growth | 208.07% | 55.77% | -53.93% | 274.33% | -100% | - | - | - | - | - |
OMER SEC Filings & Documents
Omeros Corporation (OMER) SEC filings — annual & quarterly reports (10-K, 10-Q)
OMER Frequently Asked Questions
Omeros Corporation (OMER) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Omeros Corporation (OMER) grew revenue by 0.0% over the past year. Growth has been modest.
Omeros Corporation (OMER) reported a net loss of $121.2M for fiscal year 2024.
Dividend & Returns
Omeros Corporation (OMER) had negative free cash flow of $105.3M in fiscal year 2024, likely due to heavy capital investments.
Explore More OMER
Omeros Corporation (OMER) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates